GLPwatch
Papers (9189)
Page 92 of 154, ranked by citation count.
- High price and demand for semaglutide means lack of access for US patients.
- IDegLira for the real-world treatment of type 2 diabetes in Italy. Final results from the REX observational study.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats.
- Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
- Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials
- A Glucagon-like Peptide 1 Analog Protects Mitochondria and Attenuates Hypoxia-Reoxygenation Injury in Cultured Cardiomyocytes.
- CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure.
- Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro.
- Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?
- Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition.
- Weight loss breaks the bond between nonalcoholic fatty liver disease and cardiovascular diseases: A clinical and epidemiological perspective.
- Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting.
- Hot weight loss drugs tested against addiction.
- Implications of immortal person-time when outcomes are nonfatal.
- Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials.
- The transcription factor B-cell lymphoma (BCL)-6 modulates pancreatic {beta}-cell inflammatory responses.
- [Liraglutide promotes proliferation and migration of cardiac microvascular endothelial cells through PI3K/Akt and MAPK/ERK signaling pathways].
- Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.
- Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial.
- Triple Agonism Based Therapies for Obesity.
- Effectiveness of a hybrid approach in integrating GLP-1 agonists and lifestyle guidance for obesity and pre-diabetes management: RWE retrospective study.
- Liraglutide preserves intracellular calcium handling in isolated murine myocytes exposed to oxidative stress.
- Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
- Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.
- Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications.
- PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.
- Tirzepatide-associated starvation ketoacidosis.
- Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update.
- The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes.
- Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia.
- Oral semaglutide in type 2 diabetes mellitus: Comprehensive review, critical appraisal and clinical consideration of its use in India.
- Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
- Monitoring β-Cell Survival After Intrahepatic Islet Transplantation Using Dynamic Exendin PET Imaging: A Proof-of-Concept Study in Individuals With Type 1 Diabetes.
- Dual effects of dulaglutide on glycemic control and knee osteoarthritis pain in elderly patients with Type 2 diabetes.
- Advances in the treatment of type 2 diabetes: impact of dulaglutide.
- Semaglutide or Placebo for Nonalcoholic Steatohepatitis.
- Real-World Effectiveness of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists (OW GLP-1RAs) in Comparison with Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) for Glycemic Control and Weight Outcomes in Type 2 Diabetes Mellitus (RELATE).
- Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data.
- Which is the optimal antiobesity agent for patients with nonalcoholic fatty liver disease?
- Assessment of glucagon-like peptide-1 analogue and renin inhibitor on the binding and regulation of GLP-1 receptor in type 1 diabetic rat hearts.
- The Influence of GLP1 on Body Weight and Glycemic Management in Patients with Diabetes-A Scientometric Investigation and Visualization Study.
- Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes.
- Evaluation of GLP-1 Receptor Agonists in Combination With Multiple Daily Insulin Injections for Type 2 Diabetes.
- The combination of dulaglutide and biguanide reduced bodyweight in Japanese patients with type 2 diabetes.
- Preparation of [<sup>177</sup>Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 for radiotherapy of insulinoma: a detailed insight into the radiochemical intricacies.
- Effect of Semaglutide on High-Fat-Diet-Induced Liver Cancer in Obese Mice.
- Improved human islet preparations using glucocorticoid and exendin-4.
- Association between Symptoms of Depression and Generalised Anxiety Disorder Evaluated through PHQ-9 and GAD-7 and Anti-Obesity Treatment in Polish Adult Women.
- Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.
- Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
- Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes.
- Kinetic control of Phytic acid/Lixisenatide/Fe (III) ternary nanoparticles assembly process for sustained peptide release.
- Novel antidiabetic nutrients identified by in vivo screening for gastric secretion and emptying regulation in rats.
- Dulaglutide treatment reverses depression-like behavior and hippocampal metabolomic homeostasis in mice exposed to chronic mild stress.
- The first successful desensitization protocol in exenatide allergy: a case report.
- Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes.
- Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus.
- Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: a systematic review and meta-analysis.
- Anti-inflammatory potential of liraglutide, a glucagon-like peptide-1 receptor agonist, in rats with peripheral acute inflammation.